MARTEK BIOSCIENCES CORP
EXHIBIT 10.56
<DOCUMENT>
<TYPE>EX-10.56
<SEQUENCE>8
<FILENAME>w89906exv10w56.htm
<DESCRIPTION>EXHIBIT 10.56
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w56</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P align="right"><FONT size="2">EXHIBIT 10.56</FONT>
<P align="center"><FONT size="2"><B>MARTEK BIOSCIENCES KINGSTREE CORPORATION<BR>
SECOND AMENDED AND RESTATED AND SUBSTITUTED PROMISSORY NOTE</B>
</FONT>
<P align="right"><FONT size="2"><B>Baltimore, Maryland</B></FONT>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="41%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="54%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" ALIGN="LEFT"><FONT size="2"><B><U>$10,000,000.00</U></B></FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="RIGHT" valign="top"><FONT size="2">
<B><U>Date: September&nbsp;5, 2003</U></B></FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>FOR VALUE RECEIVED, </B>Martek Biosciences Kingstree Corporation, a Delaware
corporation (the <B>&#147;Company&#148;</B>), does hereby promise to pay to the order of
Genencor International, Inc., a Delaware corporation
<B>(&#147;Genencor&#148;)</B> or its permitted assigns (the
<B>&#147;Holder&#148;</B>), at its office at 200 Meridian Center
Boulevard, Rochester, New York 14618 (or at such other place or places as
Holder may designate from time to time upon reasonable notice to the Company),
the principal sum of <B>TEN MILLION AND NO/100 DOLLARS ($<U>10,000,000.00</U>)</B> under the
terms and conditions of this Second Amended and Restated and Substituted
Promissory Note (this <B>&#147;Note&#148;</B>).
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FermPro Manufacturing, LP <B>(&#147;FermPro&#148;), </B>a Georgia limited partnership,
Astral Technologies, Inc., a South Carolina corporation and the general partner
of FermPro, and Martek Biosciences Corporation, a Delaware corporation, on
behalf of itself and the Company, have entered into that certain Asset Sale and
Purchase Agreement dated as of July&nbsp;21, 2003 (the <B>&#147;Fermpro Asset Sale and
Purchase Agreement&#148;) </B>pursuant to which the Company assumed the obligations of
Fermpro under the Amended and Restated and Substituted Promissory Note dated
May&nbsp;4, 1994 to the order of IBIS Limited Partnership, a North Carolina limited
Partnership <B>(&#147;IBIS&#148;),</B> as amended on April&nbsp;3, 1996 (the <B>&#147;Amended Note&#148;</B>). To
facilitate the assumption of the Amended Note, it is necessary to amend and
modify certain terms of the Amended Note, and the Company and Genencor, as
assignee of IBIS, have entered into the Note for the purposes of amending and
restating the Amended Note.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Security</U>.</B> This Note is secured by a Purchase Money Mortgage,
Assignment of Rents and Leases, Security Agreement and Fixture Filing dated
April&nbsp;27, 1994 and duly recorded in Book 338 at Page 96 in the Office of the
Clerk of Court of Williamsburg County, South Carolina, and amended on May&nbsp;4,
1994, April&nbsp;3, 1996 and of even date herewith (the <B>&#147;Mortgage&#148;</B>), each amendment
as filed or to be filed in the Office of the Office of the Clerk of Court of
Williamsburg County, South Carolina and a Security Agreement dated as of April
27, 1994 as amended on May&nbsp;4, 1994, April&nbsp;3, 1996 and of even date herewith
(the <B>&#147;Security Agreement&#148;</B>, and with the Mortgage, the <B>&#147;Mortgage Instruments&#148;</B>).
The Mortgage Instruments, the Non Compete Covenant in Assigne&#146;s Favor (as
defined in the Security Agreement) and the TMA (as defined in the Security
Agreement) are referred to herein as the <B>&#147;Purchase Documents.&#148; </B>Any Event of
Default under any Purchase Document is an Event of Default under the terms of
this Note.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Amendment</U>.</B> This Note is an amendment and restatement to the Amended Note
and is issued in substitution therefor.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Interest Accrual</U>.</B> The outstanding principal balance of this Note shall
bear interest from the date hereof until payment in full at the rate of five
per cent <I>(<U>5%</U>) </I>per annum.
</FONT>
<P align="center"><FONT size="2">&nbsp;</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P align="left"><FONT size="2">Interest shall he computed on the basis of a three hundred sixty-day year on
the actual number of days the principal is outstanding during each annual
interest period.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Payments of Interest and Principal</U>.</B> Payments of accrued interest shall be
made monthly on the last calendar day of each month, commencing on December
31, 2003 and on the Maturity Date (<U>as defined below</U>). Principal payments on
this Note shall be made monthly on the last calendar day of each month,
commencing on January&nbsp;31, 2004, each such principal payment in the amount
equal to Forty-one thousand six hundred sixty-seven dollars ($<U>41,667</U>). The
entire unpaid principal amount plus accrued interest under this Note shall be
due and payable on the Maturity Date. Except as provided for under Prepayment,
Payments of principal and interest shall be paid in lawful money of the United
States of America at the office of the Holder as indicated in the opening
paragraph or at such other place as Holder may designate from time to time.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Prepayment</U>.</B> This Note may be prepaid in whole or in part, at any time,
without penalty, in cash, or in such other consideration as the Company and
Holder may agree.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Late Charges</U>.</B> In the event any payment of interest or principal is
delinquent more than fifteen (<U>15</U>) days, the Company will pay to Holder a late
charge of four percent (<U>4%</U>) of the amount of the overdue payment. This
provision for late charges shall not be deemed to extend the time for payment
or be a <B>&#147;grace period&#148;</B> or <B>&#147;cure period&#148; </B>that gives the Company the right to
cure an Event of Default. Except as otherwise may be provided by applicable
law, imposition of late charges is not contingent upon the giving of any
notice or lapse of any cure period provided for in the Mortgage Instruments.
Acceptance by Holder of any late payment(s) shall not constitute a waiver by
holder of any default hereunder.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Maturity and Release</U>.</B> If not paid earlier pursuant to the terms of this
Note, the entire outstanding principal balance plus all accrued and unpaid
interest due and payable under this Note shall be due and payable on December
31, 2014 (the <B>&#147;Maturity Date&#148;</B>). Upon payment in full of the entire outstanding
principal balance plus all accrued and unpaid interest due and payable under
this Note, Holder releases any and all security interest granted or lien or
encumbrance created in any of Company&#146;s real or personal property in connection
herewith and agrees to promptly execute, acknowledge and deliver to Company,
and do, all such additional and further acts, things, assurances, instruments,
documents as Company may reasonably request from time to time to evidence such
release.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Acceleration Period</U>.</B> In the event that (a)&nbsp;the Company shall <I>(i) </I>fail to
make the an interest or principal payment in the amount specified herein within
five (<U>5</U>) business days of the payment becoming due in accordance with the terms
hereof, or <I>(ii) </I>fail to make any other payments hereunder within five (<U>5</U>)
business days of the payment becoming due, (b)&nbsp;there is a breach of any of the
covenants and provisions contained in this Note, and such breach shall continue
for a period of at least thirty (<U>30</U>) days after notice of such, or (c)&nbsp;there is
an Event of Default under any Purchase Document (including, without limitation,
by way of cross-default), then in such event the Holder may without further
notice, declare the remainder of the principal sum, together with all interest
accrued thereon, at once due and payable. Failure to exercise this option shall
not constitute a waiver of the right to exercise the same at any other time.
The unpaid balance of this Note and any part thereof plus all accrued interest
due under this Note, shall bear interest at the rate of ten percent (<U>10%</U>) per
annum after default until paid. The
</FONT>
<P align="center"><FONT size="2">2</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P align="left"><FONT size="2">Company hereby waives protest, presentment, notice of dishonor, and notice of
acceleration of maturity. Upon default, the Holder of this Note may employ an
attorney to enforce the Holder&#146;s rights and remedies and the Company hereby
agrees to pay to the Holder reasonable attorney&#146;s fees plus all other
reasonable expenses incurred by the Holder in exercising any of the Holder&#146;s
rights and remedies upon default.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Expenses</U>.</B> Except as provided for in the last sentence of the Acceleration
Period, the Company and Holder each agree to pay their own expenses, including
the expenses and reasonable attorneys&#146; fees, paid or incurred by such party in
connection with the preparation of this Note or the amendment, modification, or
replacement of the Mortgage Instruments or otherwise in connection with the
Note. Further, the Company and Holder agrees to each pay one-half of all
expenses in connection with the filing or recordation of all financing
statements and other documents as may be required by Holder at the time or, or
subsequent to, the execution of this Note, including, without limitation, all
documentary stamps, recordation and transfer taxes, filing fees and other costs
and taxes incident to recordation of any document in connection herewith.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Business Day</U>.</B> If any payment of principal or interest shall be due on a
Saturday, Sunday or any other day on which banking institutions in the State of
Maryland are required or permitted to be closed, such payment shall be made on
the next succeeding business day and such extension of time shall be included
in computing interest hereunder.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Application of Payments</U>.</B> All sums received by holder for application to
the Note may be applied by holder to late charges, expenses, costs, interest,
principal and other amounts owing to holder in connection with the Note in the
order selected by holder in its sole discretion.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Successors and Assigns</U>.</B> This Note may not be assigned by Genencor
(or any other Holder hereof), in whole or in part, at any time, without the
prior written consent of the Company. This Note shall be binding upon the
successors and assigns of the Company and shall inure to the benefit of the
permitted successors and assigns of the Genencor.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company intends to treat this Note as <B>&#147;debt&#148; </B>and not as <B>&#147;equity&#148; </B>for
United States federal income tax purposes.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Note is made and delivered in South Carolina and shall be
governed and construed in accordance with the laws of the State of South
Carolina.
</FONT>
<P align="center"><FONT size="2"><B>&#091;<U>The remainder of this page is intentionally left blank</U>.&#093;</B>
</FONT>


<P align="center"><FONT size="2">3</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN WITNESS WHEREOF, </B>the Company has duly executed this Second Amended and
Restated and Substituted Promissory Note under seal as of the date set forth
above.
</FONT>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="53%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" valign="top" align="left"><FONT size="2"><B>MARTEK BIOSCIENCES KINGSTREE<BR>
CORPORATION</B></FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
By:
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">/s/ GEORGE P. BARKER</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><HR size="1" width="45%" noshade></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Name:
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">GEORGE P. BARKER</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Title:</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">SR. V. P. &#038; GENERAL COUNSEL</FONT></TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="2">&#091;Corporate Seal&#093;<BR>
ATTEST:<BR><BR>
&#091;ILLEGIBLE&#093;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="left"><HR size="1" width="30%" noshade></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">Secretary</FONT></TD>
</TR>
</TABLE>
</CENTER>

<P align="center"><FONT size="2">1</FONT>



</BODY>
</HTML>

</TEXT>
</DOCUMENT>
